{"id":42619,"date":"2026-10-31T06:40:00","date_gmt":"2026-10-31T05:40:00","guid":{"rendered":"https:\/\/www.abcsg.org\/abcsg-studien\/studies-open-for-enrollment\/abcsg-64-neograce\/abcsg-64-neograce-uebersicht\/"},"modified":"2026-10-31T06:59:40","modified_gmt":"2026-10-31T05:59:40","slug":"abcsg-64-neograce-uebersicht","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/abcsg-studien\/studies-open-for-enrollment\/abcsg-64-neograce\/abcsg-64-neograce-uebersicht\/","title":{"rendered":"ABCSG 64 \/ neoGRACE Overview"},"content":{"rendered":"<p>An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+\/HER2-negative early breast cancer<\/p>\n<table class=\"studienmeta-public\">\n<tbody>\n<tr>\n<td>Study start:<\/td>\n<td>Q4\/2026<\/td>\n<\/tr>\n<tr>\n<td>Coordinating Investigators:<\/td>\n<td>Christian Singer, Vienna<br \/>\nMichael Gnant, Vienna<\/td>\n<\/tr>\n<tr>\n<td>Sample size:<\/td>\n<td>80 (national)<\/td>\n<\/tr>\n<tr>\n<td>Study design:<br \/>\n<em>(Click to enlarge)<\/em><\/td>\n<td><a  href=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2026\/10\/ABCSG-64_Study-design.jpg\" data-rel=\"lightbox-gallery-0\" data-rl_title=\"\" data-rl_caption=\"\" title=\"\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-42627\" src=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2026\/10\/ABCSG-64_Study-design-280x158.jpg\" alt=\"ABCSG 64_Study design\" width=\"280\" height=\"158\" srcset=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2026\/10\/ABCSG-64_Study-design-280x158.jpg 280w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2026\/10\/ABCSG-64_Study-design-768x432.jpg 768w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2026\/10\/ABCSG-64_Study-design.jpg 1280w\" sizes=\"auto, (max-width: 280px) 100vw, 280px\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+\/HER2-negative early breast cancer Study start: Q4\/2026 Coordinating Investigators: Christian Singer, Vienna Michael Gnant, Vienna Sample size: 80 (national) Study design: (Click to enlarge)<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":42617,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"page-einzel-studie.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-42619","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/42619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=42619"}],"version-history":[{"count":3,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/42619\/revisions"}],"predecessor-version":[{"id":42629,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/42619\/revisions\/42629"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/42617"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=42619"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=42619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}